Metabolism of amyloid-â protein may be affected in depression

Journal of Clinical Psychiatry

Volumn 73, Issue 1, 2012, Pages 115-120

  Baba, Hajime ^a,b   Nakano, Yoshiyuki ^a,b   Maeshima, Hitoshi ^a,b   Satomura, Emi ^a   Kita, Yohei ^a   Suzuki, Toshihito ^a,b   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Juntendo University Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E4; BIOLOGICAL FACTOR; BIOLOGICAL MARKER; IMIPRAMINE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATHOPHYSIOLOGY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN METABOLISM; RISK FACTOR; ADOLESCENT; AGE; ALLELE; BLOOD; GENETICS; MIDDLE AGED;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS;

EID: 84856302889     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06766     Document Type: Article

References (47)

1. Devanand DP, Sano M, Tang MX, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry. 1996;53(2):175-182. PubMed
2. Wilson RS, Barnes LL, Mendes de Leon CF, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002;59(3):364-370. PubMed
3. Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530-538. PubMed
4. Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003;60(5):753-759. PubMed
5. Geerlings MI, den Heijer T, Koudstaal PJ, et al. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology. 2008;70(15):1258-1264. PubMed
6. Schröder J, Pantel J, Ida N, et al. Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry. 1997;2(6):505-507. doi:10.1038/sj.mp.40313 PubMed
7. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58(3):373-379. PubMed
8. Mehta PD, Pirttila T, Patrick BA, et al. Amyloid-β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 2001;304(1-2):102-106. doi:10.1016/S0304- 3940(01)01754-2 PubMed (Pubitemid 32377212)
9. Giedraitis V, Sundelöf J, Irizarry MC, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett. 2007;427(3):127-131. doi:10.1016/j.neulet.207.09.023 PubMed (Pubitemid 47633799)
10. Le Bastard N, Aerts L, Leurs J, et al. No correlation between time-linked plasma and CSF Aβ levels. Neurochem Int. 2009;55(8):820-825. doi:10.1016/j.neuint.209.08.06 PubMed
11. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21(2):372-381. PubMed
12. Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid- βprotein is elevated in late-onset Alzheimer disease families. Neurology. 2008;70(8):596-606. doi:10.1212/01.wnl.0278386.035.21 PubMed (Pubitemid 351294637)
13. Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid-β protein levels. Arch Neurol. 2003;60(7):958-964. doi:10.101/archneur.60.7.958 PubMed (Pubitemid 36858355)
14. Sobów T, Flirski M, Kłoszewska I, et al. Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars). 2005;65(2):117-124. PubMed
15. Lopez OL, Kuller LH, Mehta PD, et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology. 2008;70(19):1664-1671. doi:10.1212/01.wnl.030696.82017.6 PubMed (Pubitemid 351644132)
16. Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64(3):354-362. doi:10.101/archneur.64.3.354 PubMed (Pubitemid 46425689)
17. van Oijen M, Hofman A, Soares HD, et al. Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5(8):655-660. doi:10.1016/S1474-42(06)70501-4 PubMed (Pubitemid 44062411)
18. Lambert JC, Schraen-Maschke S, Richard F, et al. Association of plasma amyloid-β with risk of dementia: the prospective Three-City Study. Neurology. 2009;73(11):847-853. doi:10.1212/WNL.0b013e3181b7848 PubMed
19. Pomara N, Doraiswamy PM, Willoughby LM, et al. Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res. 2006; 31(3):341-349. doi:10.107/s1064-05-9029-z PubMed (Pubitemid 43829323)
20. Qiu WQ, Sun X, Selkoe DJ, et al. Depression is associated with low plasma Aβ42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry. 2007;22(6):536-542. doi:10.102/gps.1710 PubMed (Pubitemid 46951751)
21. Sun X, Mwamburi DM, Bungay K, et al. Depression, antidepressants, and plasma amyloid β (beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry. 2007;62(12):1413-1417. doi:10.1016/j.biopsych.207.01.03 PubMed
22. Sun X, Steffens DC, Au R, et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry. 2008;65(5):542-550. doi:10.101/archpsyc.65.5.542 PubMed
23. Kita Y, Baba H, Maeshima H, et al. Serum amyloid-β protein in young and elderly depression: a pilot study. Psychogeriatrics. 2009;9(4):180-185. doi:10.1/j.1479-8301.209.0293.x PubMed
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/02-3956(75)9026-6 PubMed
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
26. Inagaki A, Inada T. Dose equivalence of psychotropic drugs, pt 18: dose equivalence of psychotropic drugs. Jpn J Clin Psychopharmacol. 2006;9(7):1443-1447.
27. Wenham PR, Newton CR, Price WH. Analysis of apolipoprotein E genotypes by the Amplification Refractory Mutation System. Clin Chem. 1991;37(2):241-244. PubMed
28. Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev. 1986;7(3):284-301. PubMed
29. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63(2):161-167. PubMed
30. Coffey CE, Figiel GS, Djang WT, et al. Subcortical hyperintensity on magnetic resonance imaging: a comparison of normal and depressed elderly subjects. Am J Psychiatry. 1990;147(2):187-189. PubMed
31. Krishnan KR. Neuroanatomic substrates of depression in the elderly. J Geriatr Psychiatry Neurol. 1993;6(1):39-58. PubMed
32. Greenwald BS, Kramer-Ginsberg E, Krishnan RR, et al. MRI signal hyperintensities in geriatric depression. Am J Psychiatry. 1996;153(9): 1212-1215. PubMed
33. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154(4):497-501. PubMed
34. Tupler LA, Krishnan KR, McDonald WM, et al. Anatomic location and laterality of MRI signal hyperintensities in late-life depression. J Psychosom Res. 2002;53(2):665-676. doi:10.1016/S02-39(02)0425-7 PubMed (Pubitemid 36292446)
35. Fujikawa T, Yamawaki S, Touhouda Y. Incidence of silent cerebral infarction in patients with major depression. Stroke. 1993;24(11):1631-1634. PubMed
36. Nakano Y, Baba H, Maeshima H, et al. Executive dysfunction in medicated, remitted state of major depression. J Affect Disord. 2008; 111(1):46-51. doi:10.1016/j.jad.208.01.027 PubMed
37. Sun X, Chiu CC, Liebson E, et al. Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis Assoc Disord. 2009;23(3):238-244. doi:10.1097/WAD.0b013e31819cb3ac PubMed
38. Gudmundsson P, Skoog I, Waern M, et al. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry. 2007;15(10):832-838. doi:10.1097/JGP.0b013e3180547091 PubMed
39. Pomara N, Murali Doraiswamy P. Does increased platelet release of Aβpeptide contribute to brain abnormalities in individuals with depression? Med Hypotheses. 2003;60(5):640-643. doi:10.1016/S0306-987(02)0380-8 PubMed
40. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351(1):56-67. PubMed
41. Elovainio M, Puttonen S, Pulkki-Råback L, et al. Association of the apolipoprotein E gene, its promoter polymorphisms and haplotypes with depressive symptoms: the Cardiovascular Risk in Young Finns Study. Neuropsychobiology. 2008;58(2):91-96. doi:10.159/016235 PubMed
42. Surtees PG, Wainwright NW, Bowman R, et al. No association between APOE and major depressive disorder in a community sample of 17,507 adults. J Psychiatr Res. 2009;43(9):843-847. doi:10.1016/j.jpsychires.208.12.01 PubMed
43. Irie F, Masaki KH, Petrovitch H, et al. Apolipoprotein E ε4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: the Honolulu-Asia Aging Study. Arch Gen Psychiatry. 2008;65(8):906-912. doi:10.101/archpsyc.65.8.906 PubMed
44. Nelson RL, Guo Z, Halagappa VM, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007;205(1):166-176. doi:10.1016/j.expneurol.207.01.037 PubMed (Pubitemid 46617502)
45. Sun X, Sato S, Murayama O, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett. 2002;321(1-2):61-64. doi:10.1016/S0304-3940(01)02583-6 PubMed (Pubitemid 34185499)
46. Phiel CJ, Wilson CA, Lee VM, et al. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature. 2003;423(6938): 435-439. doi:10.1038/nature01640 PubMed (Pubitemid 36626994)
47. Qing H, He G, Ly PT, et al. Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med. 2008;205(12):2781-2789. doi:10.1084/jem.208158 PubMed